Company / Free Cash Flow
ELITE PHARMACEUTICALS INC /NV/ Free Cash Flow History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$5.8M
FY2024
5-year range
-$4.0M / $6.0M
FY2021-FY2024
Trend
+244.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow changed +244% YoY in FY2024, a notable deviation from the 3-year average annual change of +12%.
Based on SEC 10-K filings.
$6M in FY2024 with a 3-year CAGR of -1.0%.
Improved from -$2M to $6M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -1.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -1.0%, indicating a declining trend.
- In FY2024, free cash flow increased 244.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $5.8M | +244.2% |
| FY2023 | -$4.0M | -68.7% |
| FY2022 | -$2.4M | -139.9% |
| FY2021 | $6.0M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026